RxDoctor Payments Data

Cruz Ranea, MD

General Practice · Clermont, FLNPI 1497409593

Payments from drug & device makers

$1,404in general payments, 2019–2025

Across 33 payments — averaging $42.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$572
  • AstraZeneca$425
  • Exact Sciences$152
  • Amgen$110
  • Lilly USA, LLC$101
  • Novo Nordisk$24
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$1,404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK11$572
AstraZeneca6$425
Exact Sciences7$152
Amgen1$110
Lilly USA, LLC6$101
Novo Nordisk1$24
Boehringer Ingelheim1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,404 in reported general payments places this provider in the 80th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$3,241
Medicare patients
14
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$103,242
FarxigaDapagliflozin Propanediol58$75,852
EliquisApixaban59$74,956
TrulicityDulaglutide44$62,620
OzempicSemaglutide40$54,542
XareltoRivaroxaban22$33,597
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$27,017
MounjaroTirzepatide19$19,456
JanuviaSitagliptin Phosphate13$19,228
Tresiba Flextouch U-100Insulin Degludec15$10,682
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$6,059
SymbicortBudesonide/Formoterol Fumarate11$3,793
Atorvastatin Calcium491$3,571
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,538
Celecoxib113$3,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$103,24268 claims
Lilly USA, LLCTrulicity, Mounjaro$101$82,07663 claims
AstraZenecaFarxiga, Symbicort$425$79,64569 claims
Novo NordiskOzempic$24$54,54240 claims
GSKTrelegy Ellipta$572$27,01717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,901 general practice providers in Florida.

Other general practice in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →